COVID-era generic drug price changes: No news is good news

CMS has released their latest round of drug pricing data – another peek into the functionality of the prescription drug supply chain amid the COVID-19 pandemic. As we highlighted in the June and July NADAC reports, generic drug prices are weathering the pandemic storm. In fact, not only have the predictions of massive increases failed to come to fruition, but instead, generic drug prices are falling. This month continues that trend. Our latest report digs into the numbers using the latest NADAC drug pricing data from CMS.

Slicing up the Pie: New dashboard launched to track drugmaker market share

If you’re trying to discover reasons for why drug prices go up or down, one of the best things to look at is supply and demand. A new federal antitrust lawsuit alleges that several generic drugmakers were colluding in an effort to protect market share and raise prices. To get a better sense of what was happening in the market at the time the alleged collusion took place, it helps to track a drug’s market share over time. Using Medicaid utilization data and other public datasets, we have now launched a new dashboard to provide a crumb trail for those looking to determine the market distribution of drug manufacturers as prices fluctuate.

Ben LinkDecember 21, 2018Generic, Shortages, Antitrust, NADAC, Medicaid, Prilosec, Omeprazole, Acetazolamide, Teva, Heritage, OTC, Major Pharmaceuticals, Visualization

What’s happening to generic drug prices? December 2018 NADAC Survey Update

It’s NADAC survey results week, which means it’s time for our fifth installment of “what happened to generic drug prices last month.” On a positive note, it looks like there was a bit of net deflation. But overall it was a less than stellar month for generic deflation - it was the first month (since we started this monthly review) where we saw more generic drug price increases then decreases. As always, the details matter, and we’re here to provide them for you. Check out our latest drug pricing report for a lot of important updates, plus an updated NADAC Packed Bubble Chart!

Ben LinkDecember 21, 2018NADAC, Medicaid, ADHD, Concerta, Methylphenidate, Shortages, Norvir, HIV, AbbVie, Zebeta

What’s happening to generic drug prices? October 2018 NADAC Survey Update

It’s NADAC survey results week, which means it’s time for our third installment of “what happened to generic drug prices last month.” It looks like there was a bit of net deflation, but overall, there were an equal number of price increases and decreases. But as always, the details matter. Check out our latest drug pricing report for a lot of important updates, plus an updated NADAC Packed Bubble Chart!